The investigators reported lower [18F]THK5117 uptake in MCI compared with AD subjects, though both were raised compared to healthy controls, thus demonstrating the ability of the tau tracer to distinguish the spectrum of the Alzheimer disease process [66]. This evidence concerns the gene MAPT and Alzheimer disease.